TABLE 2.
In vivo anticancer effects of citrus peel extract1
Sample | Animal models | Dose (route) | Duration | Effects | Reference |
---|---|---|---|---|---|
Citrus junos | HT-29 cells implanted mice | 100 mg/kg/d (i.p.) | 4 wk | Reduced tumor size, disease activity index and colon shortening | 113 |
C. aurantium | A549 cells injected in mice tail vein | Twice weekly (i.p.) | 5 wk | Reduced cancer metastasis | 40 |
C. reticulata | Treated leukemic cells injected into mice | — | 2/10 wk | Reduced number of tumor cells and increased mice survival time | 106 |
C. sinensis | AOM-induced carcinogenesis in mice | 0.2% in diet | 26 wk | Reduced number and size of ACF, tumor burden, and incidence | 128 |
C. sinensis | Western diet inducing cancer | 0.25%/0.5% in diet | 9 wk | Reduced tumor number, multiplicity, and induced apoptosis | 129 |
Multiple citrus | DMBA-induced carcinogenesis in mice | 100/200 µL twice weekly (cream application) | 20 wk | Reduced epidermal thickness, number of papillomas, tumor incidence, and tumor weight | 127 |
C. unshiu | Double-TPA application to ICR mouse skin | 8.1 nmol/30 min | 24 h | Inhibit NO and O2− generation | 56 |
Multiple citrus | PC-3 cells implanted in mice | 1/2 mg/kg 5 d/wk (i.p.) and 2 or 4 mg/kg 5 d/wk (o.p.) | 3 wk | Suppressed tumor size | 126 |
Multiple citrus | AOM-induced carcinogenesis in mice | 100/200 µL 5 d/wk (o.p.) | 6 wk | Reduced number of ACF | 126 |
C. iyo | DU145 cells implanted in mice | 50/200 mg/kg thrice weekly (i.p.) | 4 wk | Suppressed tumor growth | 75 |
C. depressa | TEWL and epidermal thickness in UVB-irradiated mouse skin | 100 µL of 10%/d | 1 wk | Reduce photoaging in mice | 130 |
C. sinensis | HepG2 cells implanted in mice | 1/10 mg/kg thrice weekly in diet | 3 wk | Reduced tumor growth | 120 |
C. sinensis | AOM-induced carcinogenesis in mice | 0.01/0.05% in diet | 4/18 wk | Reduced number of ACF | 125 |
ACF, aberrant crypt foci; AOM, azoxymethane; DMBA, 7,12-dimethylbenz(α)anthracene; ICR, Institute of Cancer Research; i.p., intraperitoneal injection; o.p., oral injection; TEWL, transepidermal water loss; TPA, tissue plasminogen activator.